Leptin-Related Trial NCT05117983 Now Active, Not Recruiting

On August 20, 2026, the trial registered as NCT05117983 was listed with a status of active, not recruiting. The study is titled "Non-invasive Brain Stimulation Normalizes Dopaminergic Transmission in the Frontostriatal Circuit to Alleviate Depression With Metabolic Disorders." The trial phase is listed as not applicable. This update relates to research involving leptin, a compound with approved regulatory status. The current status means the trial is ongoing but is no longer enrolling new participants at this time. No outcomes, results, or efficacy data have been reported as part of this status update. The registry entry does not include findings on dopaminergic transmission changes or depression symptom outcomes at this stage. Readers should note that a status update of this kind reflects only the administrative and enrollment stage of the trial, not any conclusions about safety or effectiveness. Further updates may be issued as the trial progresses toward completion or results reporting. For additional background on leptin, including its regulatory status and general context, readers can consult the compound overview.